BAM
IRD

Byrne Asset Management’s Opus Genetics IRD Stock Holding History

Byrne Asset Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,176
Closed -$8K – 556
2021
Q4 		$8K Buy
+2,176
New +$8.72K 0.01% 416

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Byrne Asset Management's IRD Position: Q1 2022 in Review

Byrne Asset Management sold out of Opus Genetics (IRD) in Q1 2022, closing a stake of 2,176 shares — an estimated $8K sold.

Byrne Asset Management first reported a position in IRD in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 41 funds tracked by Wall St. Rank hold IRD as of Q1 2022.

  • Byrne Asset Management reported no remaining Opus Genetics position as of Q1 2022 after selling out during the quarter.
  • Byrne Asset Management sold 2,176 Opus Genetics shares in Q1 2022, an estimated $8K.
  • Byrne Asset Management first reported a position in Opus Genetics in Q4 2021 and held it in 1 quarter.
  • Byrne Asset Management's Opus Genetics position peaked at $8K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2022.

Based on Byrne Asset Management's 13F filing for Q1 2022, filed 5 Apr 2022.